PearceIP Blog

Read our latest updates & insights

Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.

Amazon invention a mere business solution and not patentable

By Naomi Pearce | Feb 16, 2021

Read more

Date: 16 February 2021Forum: Australian Patent OfficeDelegate: Kevin Restrick
Background
Under Australian law, business methods are not patent eligible because they are ...
How medicine repurposing could unravel the pharma industry in Australia

By Naomi Pearce | Feb 15, 2021

Read more

As discussed in Part 1 of this blog series, TGA has invited submissions by 23 March 2021 on its consultation paper released last Thursday designed to facilitate indication “repurpos...
Pearce IP features its Women in Science

By Pearce IP | Feb 15, 2021

Read more

In honour of UN International Day of Women and Girls in Science
Last Thursday was the International Day of Women and Girls in Science, marking 6 years since the United Nations...
Pearce IP BioBlast®: w/e 12 February 2021

By Naomi Pearce | Feb 15, 2021

Read more

04 Feb 2021 | Roche reported a huge erosion of its year on year CER growth in key areas, attributing this decline to COVID-19 impacts and biosimilars. Roche reported the YoY CER growth ...
Fujifilm and Mylan launch Hulio® (biosimilar adalimumab) in Japan

By Bioblast Editor | Feb 15, 2021

Read more

Fujifilm Kyowa Kirin Biologics and Mylan announced the launch of Hulio® in Japan. Hulio® is available in a 40mg/0.8mL syringe and pen presentation (indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriasis, ankylosing spondylitis, Entero-Behcet’s Di...
Celltrion's Yuflyma® (biosimilar adalimumab) approved in the EU

By Bioblast Editor | Feb 15, 2021

Read more

Celltrion announced it received EC marketing authorisation for Yuflyma® (biosimilar adalimumab) across all indications. This is the first approval of a high concentration, low-volume biosimilar adalimumab. The EPAR is yet to be published by EMA.
Tabuk partners with Prestige on Tuznue®(biosimilar trastuzumab)

By Bioblast Editor | Feb 13, 2021

Read more

Saudi Arabia’s Tabuk Pharmaceuticals announced it has reached an exclusive licensing and distribution agreement with Korea’s Prestige Biopharma for the commercialisation of Tuznue® (biosimilar trastuzumab). Under the agreement, Tabuk will receive exclusive right...
EU approves Biocon Biologics/Viatris' Kixelle®(biosimilar insulin aspart)

By Bioblast Editor | Feb 12, 2021

Read more

Biocon Biologics and Viatris announced Kixelle® (biosimilar insulin aspart) has received marking authorisation approval in the EU.
Roche releases Ph III results of follow-on faricimab

By Bioblast Editor | Feb 12, 2021

Read more

Roche announced new Ph III data shows faricimab (given at intervals of up to four months) is non-inferior compared to aflibercept (given every two months). This may reduce the treatment burden for patients suffering from diabetic macular edema and neovascular age-related ma...
Exclusive licensees: are you stuck in a “No Standing” zone?

By Naomi Pearce | Feb 11, 2021

Read more

Under Australian law, patent infringement proceedings may be started in the Australian Federal Court only by a patentee or an exclusive licensee.[1] When it comes to determining th...